



Plasmodium falciparum Cyclic GMP-Dependent Protein Kinase Interacts with a Subunit of the Parasite Proteasome

K. Govindasamy,^a R. Khan,^a M. Snyder,^a H. J. Lou,^b P. Du,^c H. M. Kudyba,^d  V. Muralidharan,^d B. E. Turk,^b P. Bhanot^a

^aDepartment of Microbiology, Biochemistry, and Molecular Genetics, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA

^bDepartment of Pharmacology, Yale University School of Medicine, New Haven, Connecticut, USA

^cDepartment of Information Systems and Technology, New Jersey Medical School, Rutgers University, Newark, New Jersey, USA

^dCenter for Tropical and Emerging Global Diseases, Department of Cellular Biology, University of Georgia, Athens, Georgia, USA

ABSTRACT Malaria is caused by the protozoan parasite *Plasmodium*, which undergoes a complex life cycle in a human host and a mosquito vector. The parasite's cyclic GMP (cGMP)-dependent protein kinase (PKG) is essential at multiple steps of the life cycle. Phosphoproteomic studies in *Plasmodium falciparum* erythrocytic stages and *Plasmodium berghei* ookinetes have identified proteolysis as a major biological pathway dependent on PKG activity. To further understand PKG's mechanism of action, we screened a yeast two-hybrid library for *P. falciparum* proteins that interact with *P. falciparum* PKG (PfPKG) and tested peptide libraries to identify its phosphorylation site preferences. Our data suggest that PfPKG has a distinct phosphorylation site and that PfPKG directly phosphorylates parasite RPT1, one of six AAA⁺ ATPases present in the 19S regulatory particle of the proteasome. PfPKG and RPT1 interact *in vitro*, and the interacting fragment of RPT1 carries a PfPKG consensus phosphorylation site; a peptide carrying this consensus site competes with the RPT1 fragment for binding to PfPKG and is efficiently phosphorylated by PfPKG. These data suggest that PfPKG's phosphorylation of RPT1 could contribute to its regulation of parasite proteolysis. We demonstrate that proteolysis plays an important role in a biological process known to require *Plasmodium* PKG: invasion by sporozoites of hepatocytes. A small-molecule inhibitor of proteasomal activity blocks sporozoite invasion in an additive manner when combined with a *Plasmodium* PKG-specific inhibitor. Mining the previously described parasite PKG-dependent phosphoproteomes using the consensus phosphorylation motif identified additional proteins that are likely to be direct substrates of the enzyme.

KEYWORDS *Plasmodium falciparum*, kinase, mechanism, proteasome, substrate

Despite recent progress, malaria remains a devastating disease that kills over 400,000 people annually (1). Its causative agent, the protozoan parasite *Plasmodium*, undergoes a complex life cycle in the human host and the *Anopheles* mosquito vector (2). *Plasmodium* organisms are transmitted to humans by mosquitoes in the form of sporozoites. Sporozoites infect hepatocytes in the liver, within which they differentiate into exo-erythrocytic forms that give rise to hepatic merozoites. Hepatic merozoites invade erythrocytes and commence the symptomatic stage of infection. Some asexually replicating erythrocytic-stage parasites form dormant sexual stages, termed gametocytes. Gametocytes develop into gametes in the mosquito midgut when ingested in the blood meal. Zygotes, resulting from the fertilization of male and female gametes, differentiate into ookinetes. Ookinetes invade the midgut epithelium and give rise to oocysts within which the parasite differentiates to form sporozoites. Sporozoites invade salivary glands and are transmitted to a new host through the bite of the infected mosquito.

Citation Govindasamy K, Khan R, Snyder M, Lou HJ, Du P, Kudyba HM, Muralidharan V, Turk BE, Bhanot P. 2019. *Plasmodium falciparum* cyclic GMP-dependent protein kinase interacts with a subunit of the parasite proteasome. *Infect Immun* 87:e00523-18. <https://doi.org/10.1128/AI.00523-18>.

Editor John H. Adams, University of South Florida

Copyright © 2018 American Society for Microbiology. All Rights Reserved.

Address correspondence to P. Bhanot, bhanotpu@njms.rutgers.edu.

Received 9 July 2018

Returned for modification 7 August 2018

Accepted 29 September 2018

Accepted manuscript posted online 15 October 2018

Published 19 December 2018

Second messenger signaling, especially through cyclic GMP (cGMP), plays a central role at several steps of this complex life cycle. cGMP signals are transduced primarily through the cGMP-dependent protein kinase (PKG) of the parasite. PKG is a serine/threonine kinase whose activity is regulated by cGMP. cGMP binding to the regulatory domain of the enzyme triggers an allosteric change (3) that activates the catalytic domain. *Plasmodium* PKG activity is essential for the parasite's invasion of and egress from hepatocytes (4, 5) and erythrocytes (6, 7) and for its differentiation from gametocytes to gametes (8). It is also required for ookinete and sporozoite motility (5, 8, 9). *Plasmodium* PKG's role in these different processes is likely explained by its regulation of phosphoinositide metabolism, which generates Ca^{2+} signals critical for merozoite egress, gametocyte activation, and ookinete motility (10, 11). In addition to phosphoinositide metabolism, protein proteolysis is a key PKG-dependent process, as revealed by PKG-dependent phosphoproteomes in both *Plasmodium falciparum* and *Plasmodium berghei* (10, 12). Despite the vital function of *Plasmodium* PKG in a variety of cellular processes, only a few direct substrates of the kinase have been identified so far (12). Some *Plasmodium* PKG-dependent protein sites have been inferred to be direct substrates of the kinase because they fall within the consensus sequence ascribed to mammalian PKG. However, it has never been demonstrated that parasite PKG has the same phosphorylation site preferences as its mammalian homologs, with which it shares only ~43% sequence identity within the catalytic domain. Here, we define a consensus sequence for the *P. falciparum* PKG (PfPKG) preferred phosphorylation site and report PfPKG's interaction with and potential phosphorylation of the regulatory subunit of the parasite proteasome.

RESULTS

Recombinant PfPKG interacts *in vitro* with the RPT1 subunit of the 19S proteasome and HSP90. To better understand PKG's essential role through the *Plasmodium* life cycle, it is critical to define its mechanism of action, for example, through identification of its downstream substrates. To identify potential substrates of *P. falciparum* PKG (PfPKG), we conducted yeast two-hybrid screens (data not shown) for *P. falciparum* proteins that interact with the PfPKG kinase domain (amino acids [aa] 409 to 853) using a previously described prey library encoding fragments of *P. falciparum* proteins (13). As bait, we utilized the PfPKG kinase domain (aa 409 to 761) modified to carry single amino acid substitutions that are predicted to increase the affinity of eukaryotic kinases for their substrates (PfPKG E₇₀₆A and PfPKG R₇₈₁A) (14). Yeast two-hybrid screens using PfPKG E₇₀₆A and PfPKG R₇₈₁A as baits identified 17 unique prey sequences as interacting with PfPKG. Of these, two prey sequences encoded fragments of annotated *Plasmodium* proteins: RPT1 (PF3D7_1311500) consisting of amino acids 114 to 420 (RPT1₁₁₄₋₄₂₀), a subunit of the 19S regulatory particle of the proteasome, and heat shock protein 90 (PF3D7_0708400) consisting of amino acids 228 to 518 (HSP90₂₂₈₋₅₁₈). RPT1₁₁₄₋₄₂₀ and HSP90₂₂₈₋₅₁₈ retested in a split-luciferase complementation assay, which tests the ability of two proteins to reconstitute active luciferase when fused to either the amino (N)- or carboxy (C)-terminal fragments of firefly luciferase (Nfluc and Cfluc, respectively) (15) (Fig. 1A).

The split-luciferase complementation assay confirmed interaction of PfPKG E₇₀₆A and PfPKG R₇₈₁A with RPT1₁₁₄₋₄₂₀ and HSP90₂₂₈₋₅₁₈ (Fig. 1B and C). Incubating a fusion of PfPKG E₇₀₆A and the N-terminal fragment of luciferase (Nfluc-PfPKG E₇₀₆A) with a fusion of RPT1₁₁₄₋₄₂₀ and the C-terminal fragment of luciferase (Cfluc-RPT1₁₁₄₋₄₂₀) significantly increased luciferase activity. Switching fusion partners, i.e., using Nfluc-RPT1₁₁₄₋₄₂₀ and Cfluc-PfPKG E₇₀₆A or Cfluc-PfPKG R₇₈₁A, also resulted in a significant increase in luciferase activity. In contrast, there was minimal reconstitution of luciferase activity under the following conditions: (i) when Nfluc-PfPKG E₇₀₆A was incubated with the C-terminal fragment of luciferase without a fusion partner [Cfluc(-)], (ii) when Cfluc-RPT1₁₁₄₋₄₂₀ was incubated with the N-terminal fragment of luciferase without a fusion partner [Nfluc(-)], and (iii) when Cfluc-PfPKG E₇₀₆A or Cfluc-PfPKG R₇₈₁A was incubated with Nfluc(-). Fusions of HSP90 (amino acids 228 to 518) demonstrated




FIG 1 Recombinant PpPKG interacts with RPT1 and HSP90 *in vitro*. A split-luciferase protein complementation assay was used to test interaction between the PpPKG kinase domain (PpPKG E₇₀₆A and PpPKG R₇₈₁A) and a fragment of RPT1 (amino acids 114 to 420) or HSP90 (amino acids 228 to 518). The proteins were expressed (Continued on next page)

similar specific interactions with fusions containing either PfPKG E₇₀₆A or PfPKG E₇₈₁A. These results demonstrated that PfPKG interacts *in vitro* with fragments of RPT1 and PfHSP90.

We reasoned that PKG's interaction with RPT1 predicts that the proteasome participates in cellular processes that require parasite PKG, for example, host cell invasion (5). To examine the role of the parasite proteasome in this process, we tested the effect of MG132, a proteasomal inhibitor (16), on invasion of HepG2 cells by *P. berghei* sporozoites. MG132 causes a dose-dependent decrease in the fraction of sporozoites that become intracellular (Fig. 2A). These data demonstrate a role for the parasite proteasome in a cellular process that is PKG dependent. Viability of sporozoites after MG132 treatment, as measured by propidium iodide staining, was unaffected (see Fig. S1 in the supplemental material). Combinatorial treatment with MG132 and TSP, a trisubstituted pyrrole that is a specific inhibitor of *Plasmodium* PKG (5, 8, 17), has an additive effect on sporozoite invasion (Fig. 2B). Next, we tested the effect of proteasomal inhibition on *P. berghei* sporozoites that carry a hypomorphic allele of *P. berghei* PKG (PKG T₆₁₉Q-HA, where HA is a hemagglutinin tag) with reduced PKG activity (5). Invasion by T₆₁₉Q sporozoites is significantly more sensitive to MG132 than invasion by sporozoites expressing wild-type PKG (PKG-HA) (Fig. 2C). The additive effect of the MG132 and TSP combination and the sensitivity of PKG-hypomorph sporozoites to MG132 are consistent with *P. berghei* PKG (PbPKG) and the proteasome acting in the same pathway during sporozoite invasion.

Next, we tested if inhibition of PfPKG has a global effect on protein degradation in the parasite. We quantified levels of ubiquitinated proteins in schizonts treated with a specific inhibitor of *Plasmodium* PKG (8) (TSP; termed compound 1 in reference 18). PfPKG inhibition through TSP treatment did not significantly alter the total level of ubiquitinated proteins in the parasite (Fig. S2). These data suggest that PKG-mediated phosphorylation of RPT1 is likely to affect specific, as yet unidentified, client proteins.

Analysis of *P. falciparum* PKG substrate specificity. As a way to identify specific sites that are phosphorylated by PfPKG, we determined its phosphorylation site sequence specificity. We used a positional scanning peptide library approach in which the relative rate of phosphorylation is measured on a series of peptides in which each of the 20 amino acids is replaced at each of 9 positions surrounding the phosphorylation site (19) (Fig. 3A and Fig. S3A). This analysis revealed that PfPKG strongly prefers basic residues, in particular, Arg, at the -5 and -3 positions relative to the phosphorylation site. Basic residues (Arg, Lys, and His) were also preferentially phosphorylated at the -2 position. In addition, the kinase preferentially phosphorylated hydrophobic (Φ) residues at the +1 position. PPKG appeared to generally deselect acidic residues at multiple positions both upstream and downstream of the phosphorylation site. Finally, PfPKG preferred Thr over Ser as the phosphoacceptor residue. The enhanced signal for

FIG 1 Legend (Continued)

in wheat germ extracts as fusions with the N-terminal domain (Nfluc) or the C-terminal domain (Cfluc) of luciferase. Reconstitution of functional luciferase was measured as average relative light units (RLU). (A) Western blotting confirmed expression of fusion proteins in *in vitro*-transcribed/translated wheat germ extracts. These fusion proteins were used in subsequent complementation assays. Fusions with Nfluc were detected using antiserum against the N-terminal domain of firefly luciferase. Fusions with Cfluc were detected using anti-FLAG antiserum. Smaller antibody-reactive bands are the likely translation products of incomplete transcripts. Expected molecular weights were as follows: Nfluc-PfPKG E₇₀₆A, ~100 kDa; Nfluc-HSP90₂₂₈₋₅₁₈ ~85 kDa; Nfluc-RPT1₁₁₄₋₄₂₀ ~85 kDa; Cfluc-PfPKG E₇₀₆A, ~85 kDa; Cfluc-PfPKG R₇₈₁A, ~85 kDa; Cfluc-HSP90₂₂₈₋₅₁₈ ~70 kDa; Cfluc-RPT1₁₁₄₋₄₂₀ ~60 kDa. (B) Incubation of Nfluc-PfPKG E₇₀₆A with Cfluc-RPT1₁₁₄₋₄₂₀, Cfluc-PfPKG E₇₀₆A with Nfluc-RPT1₁₁₄₋₄₂₀, or Cfluc-PfPKG R₇₈₁A with Nfluc-RPT1₁₁₄₋₄₂₀ significantly increased luciferase activity. In contrast, incubation of Nfluc-PfPKG E₇₀₆A with Cfluc without a fusion partner [Cfluc(-)], Cfluc-PfPKG E₇₀₆A with Nfluc without a fusion partner [Nfluc(-)], and Cfluc-RPT1₁₁₄₋₄₂₀ with Nfluc(-) or Cfluc-PfPKG R₇₈₁A with Nfluc(-) had a minimal effect on luciferase activity. Results shown are average of three replicates \pm standard deviations. (C) Incubation of Nfluc-PfPKG E₇₀₆A with Cfluc-HSP90₂₂₈₋₅₁₈, Cfluc-PfPKG E₇₀₆A with Nfluc-HSP90₂₂₈₋₅₁₈, or Cfluc-PfPKG R₇₈₁A with Nfluc-HSP90₂₂₈₋₅₁₈ significantly increased luciferase activity. In contrast, incubation of Nfluc-PfPKG E₇₀₆A with Cfluc(-), Cfluc-PfPKG E₇₀₆A with Nfluc(-), Cfluc-RPT1₁₁₄₋₄₂₀ with Nfluc(-), or Cfluc-PfPKG R₇₈₁A with Nfluc(-) had a minimal effect on luciferase activity. Results shown are average of three replicates \pm standard deviations. Data were analyzed using an unpaired *t* test (*, *P* < 0.05; **, *P* < 0.005).




FIG 2 Sporozoite invasion requires the proteasome and PKG. (A) Treatment of sporozoites with MG132 leads to a dose-dependent decrease in sporozoite invasion. PbGFP-Luc sporozoites were treated with different doses of MG132 prior to addition to HepG2 cells. The fraction of sporozoites that are intracellular 90 min after addition to HepG2 cells was determined. Results shown are from a representative experiment (average of 4 replicates \pm standard deviations). The experiment was performed twice. (B) Treatment of sporozoites with MG132 and TSP has an enhanced effect on sporozoite invasion compared to treatment with TSP or MG132 alone. PbGFP-Luc sporozoites were treated with either TSP (0.5 μM) alone or in combination with MG132 (5 μM) prior to addition to HepG2 cells. The fraction of sporozoites that are intracellular 90 min after addition to HepG2 cells was determined. Results shown are the average of three experiments, each done in triplicate, \pm standard errors. (C) Invasion by sporozoites with reduced PKG activity (PKG T₆₁₉Q-HA) is significantly more sensitive to MG132 inhibition than invasion by wild-type sporozoites (PKG-HA). Results shown are the average of four experiments, each done in triplicate or quadruplicate \pm standard errors. Data were analyzed using an unpaired *t* test (*, *P* < 0.05; **, *P* < 0.005; ***, *P* < 0.0005; ns, not significant).




FIG 3 PfPKG has a consensus phosphorylation site distinct from that of mammalian PKG. (A) A combinatorial peptide library consisting of 182 peptide mixtures with the general sequence shown at the top of the panel was used as the substrate in PfPKG enzymatic assays. The heat map shows the relative levels of phosphorylation of peptide mixtures having the indicated amino acid present at the indicated position. The sequence logo is scaled such that the height of the letter is proportional to the level of phosphorylation of the corresponding amino acid residue at the indicated position within the peptide. The logo was prepared using enoLOGOS (53). Results shown are the average from two separate determinations. (B) The X-ray crystal structure of PfPKG (PDB accession number 5DYK) was overlaid with that of an AKT-substrate peptide complex (PDB accession number 1O6K) using PyMOL. The substrate peptide (green) is modeled bound to PfPKG (cyan; the indicated interacting residues are shown in yellow). For clarity, AKT is not shown. (C) The consensus

(Continued on next page)

peptides with fixed Thr residues at multiple positions is likely to be an artifact arising from those peptides having two potential sites of phosphorylation.

Prior analysis of the phosphorylation site specificity of mammalian PKG had revealed strong preferences for basic residues at both the -3 and the -2 positions, reminiscent of PKA (20–22). Our observation of a strong preference for Arg at the -5 position was therefore unanticipated for PfPKG. While not ascribed to PKG or PKA, selectivity for Arg at the -5 position is characteristic of a number of related mammalian kinases, most notably AKT isozymes (23). To rationalize the substrate specificity of PfPKG, we overlaid the X-ray crystal structure of an AKT-peptide complex (24) on the recently determined structure of PfPKG (Fig. 3B). In the resulting PfPKG-peptide model, Glu625 makes an ion pair with the -3 Arg residue in the substrate. In addition, three residues shared with AKT (Glu668, Tyr702, and Glu728) make polar contacts with the -5 Arg residue in the substrate. This model provides a likely explanation as to why PfPKG, like mammalian AKT, has a strong preference for Arg at the -5 position in its substrates.

To validate the results of the peptide library screen, we examined the phosphorylation rate of individual peptide substrates bearing point substitutions at residues strongly preferred in the peptide library experiments. A peptide corresponding to a phosphorylation site in the mouse protein BAD (Ser₁₁₂) that incorporates multiple residues favored by PfPKG was an efficient substrate for the kinase (Fig. 3C and Fig. S3B). Furthermore, Ala replacement of the -3 Arg residue, the -2 His residue, or the $+1$ Tyr residue decreased the efficiency of phosphorylation. We tested the phosphoacceptor residue preference of PfPKG using versions of a peptide originally designed as an optimized substrate for the mammalian kinase, AKT (AKTIDE), in which the phosphorylation site residue was either Ser or Thr. The Thr peptide was phosphorylated about 4-fold faster than the equivalent Ser peptide, confirming that PfPKG prefers Thr over Ser as the phosphoacceptor residue. Phosphorylation of AKTIDE-Thr required cGMP and was inhibited by TSP, indicating that its phosphorylation was due to PfPKG itself and not to another kinase contaminating our preparations (Fig. 3C and Fig. S3B).

To determine if RPT1 or HSP90 could be a substrate of PKG, we searched the PKG-interacting domain of each for the presence of the minimal PfPKG phosphorylation site motif, (R/K)xx(S/T), and preferred amino acids at the -5 , -2 , 0 (phosphoacceptor), or $+1$ position relative to the sequence of the putative phosphoacceptor (Fig. 3A). RPT1_{114–420} contains six putative minimal sites for PfPKG phosphorylation (Table S1). Of these six sites, two contain an Arg or Lys at the -5 position, one contains Arg, Lys, or His at the -2 position, five contain a Thr at the 0 position, and three contain a hydrophobic residue at the $+1$ position. One of the six peptides contains preferred amino acids at all of the selected positions, i.e., RARRKT₃₉₀, suggesting that it could be phosphorylated by PfPKG.

Since interaction between the target amino sequence and a kinase is a prerequisite for substrate phosphorylation, we tested if the RARRKT₃₉₀ sequence lies within the

FIG 3 Legend (Continued)

phosphorylation site of PfPKG was confirmed by determining the reaction rate of PfPKG using individual peptides as substrates. Peptides with amino acid replacements at key positions were used as substrates in PfPKG activity assays. The presumed phosphoacceptor site in each peptide is underlined. Reaction rates for each peptide were determined relative to the rate of the wild type (WT). PfPKG has a strong preference for amino acids at the -5 and $+1$ positions. PfPKG prefers Thr (AKTIDE-T versus AKTIDE-S) as the phosphoacceptor, a basic residue at the -5 position (BAD wild type versus BAD-5A), and a hydrophobic residue at the $+1$ position (BAD wild type versus BAD + 1A) relative to the phosphorylation site. It has weaker preference for peptides containing basic residues at the -2 position (BAD wild type versus BAD-2A). Results are the average of two experiments, each done in triplicate, \pm standard deviations. (D) The domain of RPT1 that contacts PfPKG contains a phosphorylation site for PfPKG. Split-luciferase complementation assays between Nfluc-PfPKG E₇₀₆A and Cfluc-RPT1_{114–420} were performed in the presence of peptides carrying either the wild-type (WT) or a mutant (T₃₉₀A) consensus phosphorylation site from RPT1_{114–420}. Wild-type peptide, but not the mutant, competed with RPT1 for interaction with PfPKG. Results are the average of three experiments, each performed in triplicate. (E) PfPKG efficiently phosphorylates peptides matching its consensus sequence present in two possible substrate proteins, RPT1 and PB_090940. Peptides with amino acid replacements at key positions were used as substrates in PfPKG activity assays. The presumed phosphoacceptor site in each peptide is underlined. Reaction rates for each peptide were determined relative to the rate of the wild type. Results are the average of three experiments, each performed using two or three replicates. Data were analyzed using an unpaired *t* test (**, $P < 0.001$; ***, $P = 0.0001$; ****, $P < 0.0001$; ns, not significant).

interaction interface of RPT1 and PfPKG. We measured the effect of adding a peptide containing RARRKT₃₉₀I to the split-luciferase complementation assay that detects interaction between RPT1_{114–420} and the PfPKG kinase domain. Addition of the peptide inhibited luciferase activity that results when RPT1_{114–420} and the PfPKG kinase domain interact in a dose-dependent manner (Fig. 3D). A nearly identical peptide in which the putative phosphoacceptor T₃₉₀ was replaced with Ala was significantly less effective in inhibiting luciferase reconstitution. These results strongly suggest that the PfPKG-contacting domain of RPT1 includes RARRKT₃₉₀I and that T₃₉₀ is likely to be the phosphoacceptor site, as predicted by the peptide library screen. To test if RARRKT₃₉₀I can be phosphorylated by PfPKG, a peptide containing the sequence was used as the substrate in a PfPKG kinase reaction (Fig. 3E, left panel; Fig. S3C). As predicted by the positional scanning approach, PfPKG specifically phosphorylated the Thr residue (T₃₉₀) that lies within the context of the consensus and not one that lies downstream (T₃₉₂). Phosphorylation was dependent on Arg at the -5 (R₃₈₅) and -3 (R₃₈₇) positions and on a hydrophobic residue at $+1$ (I₃₉₁). The phosphorylation of the peptide *in vitro* by PfPKG suggests that RPT1 could be a substrate for PKG. We tested if PfPKG phosphorylates full-length *in vitro*-transcribed/translated RPT1 but did not detect phosphorylation (data not shown). These data suggest that RPT1's phosphorylation by PfPKG may require its assembly into the 19S proteasome or posttranslational modifications that are missing in the *in vitro*-transcribed/translated protein. We cannot exclude the possibility that RPT1 is not phosphorylated by PfPKG.

HSP90_{228–518} contains five putative minimal sites for PfPKG phosphorylation (Table S1). Of these five sites, one contains Arg or Lys at the -5 position, two contain Arg, Lys, or His at the -2 position, four contain a Thr at the 0 position, three contain a hydrophobic residue at the $+1$ position, and none contains preferred amino acids at all selected positions. These sites could potentially be phosphorylated by PfPKG.

To identify more potential direct targets of PKG, we examined the PKG-dependent phosphoproteomes of ookinetes (10) and schizonts (12) for phosphopeptides that contain the preferred amino acids at positions represented by the consensus site, (R/K)xR(H/K/R)x(S/T) Φ . Phosphopeptides that are phosphorylated *in vivo* in a PKG-dependent manner and carry the preferred amino acids at positions strongly selected by PfPKG *in vitro* are most likely to be direct targets.

Analysis of the PKG-dependent phosphoproteome of ookinetes (10) shows that 820 phosphopeptides undergo a significant decrease ($P < 0.05$) in phosphorylation when PKG activity is inhibited (Table S1). Of these, 165 contain the minimal motif, (R/K)xx(S/T). Of the 165 phosphosites, 18 contain an Arg or Lys at the -5 position, 28 contain a basic residue at the -2 position, 33 contain a Thr at the 0 position, and 67 contain a hydrophobic residue at the $+1$ position. These phosphosites are more likely to be direct targets of PKG.

A peptide from PBANKA_090940, a hypothetical protein, undergoes significant PKG-dependent phosphorylation and contains the PfPKG consensus RxR(H/K/R)x(S/T) Φ . We tested the PB_090940 peptide as a substrate in the PfPKG activity assay. The PB_090940 peptide was efficiently phosphorylated by PfPKG, and phosphorylation was dependent on the identified phosphoacceptor Ser (Ser₄₅₀) (Fig. 3E, right panel, and Fig. S3C). These results are consistent with PB_090940 being a potential substrate for PfPKG.

The PKG-dependent phosphoproteome of schizonts contains 46 putative direct targets with the minimal (R/K)xx(S/T) motif (12) (Table S1). Of these, none contains an Arg or Lys at the -5 position, 10 contain a basic residue at the -2 position, 5 contain a Thr at the 0 position, and 21 contain a hydrophobic residue at the $+1$ position. Whether these sites are directly phosphorylated by PfPKG needs to be experimentally determined.

DISCUSSION

Since PKG serves multiple essential functions throughout the parasite life cycle, we attempted to better understand PKG's mechanism of action by identifying PfPKG's

consensus phosphorylation site. PfPKG's phosphorylation site motif is substantially different from the established mammalian PKG consensus sequence (20, 21), including that of human PKG1 determined previously using the same method (22). While PfPKG and mammalian PKG share a strong preference for Arg at the -3 position, mammalian PKG is nonselective at the -5 position, while PfPKG strongly prefers Arg at that position. At the -2 position, the mammalian kinase exclusively selected Lys and Arg residues, while PfPKG selected His as well. Finally, mammalian and parasite kinases have distinct phosphoacceptor residue preferences, with mammalian PKG preferring Ser and PfPKG preferring Thr. Among previously analyzed kinases, PfPKG appears most similar to mammalian ROCK1, which prefers Thr as the phosphoacceptor and has strong selectivity for Arg at the -5 and -3 positions (25, 26). We note that motifs determined on peptide substrates should not be taken as being strictly required for phosphorylation *in vivo*. Instead, true sites are expected to be highly enriched for selected residues, but no individual site will necessarily have all residues selected on peptides.

A relatively small fraction of kinase-dependent phosphorylation events found in proteomics approaches are direct substrates of the kinase. In different studies, direct substrates range from 5% to 20% of total sites identified (27, 28). Typically, sites identified in proteomics experiments that match the consensus sequence of a kinase and that decrease in abundance when the kinase is knocked out or inhibited are considered to be likely direct substrates. This criterion has been frequently used in phosphoproteomics studies to infer direct substrates of kinases (29–33).

From that standpoint, the fact that PfPKG has a novel consensus motif is significant. Our expectation is that the vast majority, if not all, of direct sites of PfPKG would have a Lys or Arg (His in rare cases) at the -3 position, with an overrepresentation of Arg or Lys at the -5 position, a basic residue at the -2 position, or a hydrophobic residue at the $+1$ position. Using these criteria to mine the PKG-dependent phosphoproteomes revealed that several proteins involved in gliding motility, such as GAP40 (34), coronin (35), MyoA (34, 36, 37), and ROM4 (38), are likely to be substrates of *Plasmodium* PKG. Phosphorylation of these proteins could be the mechanism through which PKG regulates motility, a prerequisite for invasion of host cells by different parasite stages. Future work will need to examine the biological significance of phosphorylation of these proteins by *Plasmodium* PKG.

Another parasite PKG-dependent cellular process identified by phosphoproteomics is proteolysis (12). In eukaryotic cells, regulated protein degradation by the proteasome is essential for protein homeostasis and influences processes such as the cell cycle, signal transduction, and stress response. Proteasomal function is essential in *Plasmodium* as well, as demonstrated by the potent parasitocidal activity of existing and novel proteasome inhibitors (39–42). The parasite proteasome plays an important role in many processes that also require PKG, such as erythrocytic-stage schizogony and the development of the liver stage (39, 42, 43), suggesting that PfPKG's regulation of proteolysis is biologically significant. The importance of proteasomal function during sporozoite invasion, another process that requires *Plasmodium* PKG (5), has been investigated only once before (43). This study found that treatment with the proteasomal inhibitor lactacystin did not affect the invasion rate of sporozoites and concluded that proteasomal activity is not required for sporozoite invasion (43). Our data acquired using a different proteasomal inhibitor, MG132, demonstrate that sporozoite invasion requires proteolysis. One explanation for the differential effects of lactacystin and MG132 on sporozoite invasion could be that while the former inhibits the trypsin-like activity of the $\beta 2$ subunit of the proteasome, the latter inhibits the caspase-like and chymotrypsin-like activities of the $\beta 1$ and $\beta 5$ subunits (44). For the first time, our data demonstrate that sporozoite invasion is sensitive to proteasomal inhibition, that this inhibition is additive with PKG inhibition, and that sporozoites with reduced PKG activity are more sensitive to proteasome inhibition than sporozoites with wild-type PKG. The regulation of cellular proteolysis by PKG may be evolutionarily conserved. Mammalian PKG regulates degradation of misfolded proteins in cardiomyocytes (45) via direct or indirect phosphorylation of the 19S regulatory particle of the proteasome (45,

46). Substrates of mammalian PKG in the proteasome have not been identified, but RPT6, a homolog of RPT1, is proposed as a potential target (45).

In this context, our findings that *P. falciparum* RPT1 physically interacts with the kinase domain of PfPKG and contains a consensus site for the kinase that is phosphorylated *in vitro* by PfPKG are intriguing. Characterization of the 26S proteasome in *P. falciparum* demonstrates stoichiometric incorporation of RPT1 (44), strongly suggesting that, as in higher eukaryotes, *P. falciparum* RPT1 is a critical component of the active proteasome. RPT1 is one of six AAA⁺ ATPases (RPT1 to RPT6) that are required for unfolding and translocation of the client proteins through the 19S regulatory particle prior to proteolysis by the catalytic 20S particle (47). The RPT1 homolog in *Saccharomyces cerevisiae* is phosphorylated at two Ser residues, but the responsible kinase(s) has not been identified (48, 49). Our data lead to a working hypothesis that PfPKG phosphorylation of RPT1 positively regulates proteasome function, possibly by promoting interactions between the 19S regulatory particle and client proteins. For example, phosphorylation could allosterically regulate RPT1 activity to promote substrate unfolding and translocation through the inner core of the proteasome, thereby regulating access of client proteins to the proteasome catalytic core. Alternatively, RPT1 phosphorylation could promote assembly of the 19S regulatory proteasome particle, as demonstrated for RPT6 in porcine cardiac tissue (50). Future work will focus on determining if RPT1 is a PKG substrate *in vivo*.

Our results also suggest interaction between PfPKG and PfHSP90. Interestingly, mammalian PKG regulates the activity of mammalian HSP90 (51). PfHSP90 contains several possible phosphorylation sites for PfPKG. While we did not detect phosphorylation of full-length protein in kinase assays, these data do not exclude phosphorylation of HSP90 by PfPKG *in vivo*, which may be preceded by additional posttranslational modifications absent in the *in vitro*-transcribed/translated protein. Alternatively, HSP90 could serve as a regulator of PfPKG activity. Indeed, mammalian HSP90 stabilizes and activates numerous client proteins that act in signal transduction pathways (51).

MATERIALS AND METHODS

Split luciferase assay. PfPKG_{706A} (aa 409 to 853), PfPKG_{781A} (aa 409 to 853), PF3D7_1311500 (aa 114 to 420), and PF3D7_0708400 (aa 228 to 518), were fused to N- or C-terminal fragments of firefly luciferase using previously described Nfluc and Cfluc plasmids (15). Fusion proteins were expressed using a TNT SP6 High-Yield Wheat Germ Protein Expression System (Promega) according to the manufacturer's protocol. Western blotting verified expression of Cfluc fusion proteins using anti-FLAG antibody (Sigma) and Nfluc fusion proteins using anti-N-terminal firefly luciferase (Santa Cruz Biotechnology) antibody. Equal volumes of Nfluc(-) and Cfluc(-) *in vitro* translation reactions were added to phosphate-buffered saline (PBS) supplemented with 1% bovine serum albumin (BSA) and protease inhibitors (Roche), incubated at 25°C for 2 h, and assayed for luciferase activity in duplicate or triplicate using a luminometer (BD Monolight 3010; BD Biosciences). To test the effect of peptides of luciferase reconstitution, peptides were added at 10-fold dilutions (0.71 to 714 $\mu\text{g}/\mu\text{l}$) to the incubation reaction mixture.

***In vitro* PKG activity assay.** PfPKG (aa 115 to 853) was amplified using the following primers: ATGACGATAAGGATCCAATGGG-AAAAGGTAGTTCTTTC and GCCAAGCTTCGAATCTTAAAAATCTATGTCCC AGTTG. The PCR product was cloned (In-Fusion; Clontech) into pTrcHisB digested with BamHI and EcoRI. Recombinant protein was induced in BL21 cells at 18°C using 1 mM isopropyl- β -D-thiogalactopyranoside (IPTG) and purified using Qiagen Ni-nitrilotriacetic acid (NTA) agarose according to the manufacturer's protocol. Purified PfPKG was used in kinase reactions using 50 mM HEPES (pH 7.4), 10 mM MgCl₂, 20 mM β -glycerophosphate, 2 mM dithiothreitol (DTT), 10 μM cGMP, 100 μM peptide, 0.1% BSA, 100 μM ATP, and 0.1 mM [³²P]ATP (RPT1 and PB_090940 peptides, 3,000 Ci/mmol) or [³³P]ATP (AKTIDE and BAD peptides, 0.3 $\mu\text{Ci}/\mu\text{l}$) in the presence or absence of 50 nM TSP. The peptide concentration was 10 μM (AKTIDES), 50 μM (BAD peptides), or 100 μM (RPT1 and PB_090940 peptides). Reaction mixtures were incubated at 30°C for 15 min. At 5-min intervals, 15- μl aliquots were removed and spotted onto P81 filter paper, which was washed, dried, and analyzed by scintillation counting as described previously (19).

Peptide library screening. PfPKG peptide phosphorylation site specificity was determined using a peptide library (catalog no. 62017-1; Anaspec) consisting of 180 peptide mixtures with the general sequence YAXXXXS/TXXXXAGKK-(biotin), in which 8 of the 9 X positions were a mixture of all 17 amino acids excluding Ser, Thr, and Cys (19). Within each mixture, a single X position was fixed as one of the 20 amino acids. In addition, three peptides were included in which all X positions were mixtures, but the central position was fixed as Ser, Thr, or Tyr. Peptide mixtures (50 μM) were arrayed in a 1,536-well plate in 2 μl of kinase reaction buffer (50 mM HEPES, pH 7.4, 10 mM MgCl₂, 2 mM DTT, 20 mM β -glycerophosphate, 0.1% BSA, 0.1% Tween 20) per well. Reactions were initiated by adding PfPKG to each well in 200 nl of kinase reaction buffer containing 5 μM protein kinase inhibitor (PKI), 100 μM cGMP, and 0.55 mM [γ -³³P]ATP (0.33 $\mu\text{Ci}/\mu\text{l}$). Plates were incubated for 2 h at 30°C, after which 200-nl aliquots

from each well were spotted onto streptavidin-coated membrane (Promega), which was washed as described, dried, and analyzed by phosphorimaging to measure the extent of radiolabel incorporation into each peptide.

Sporozoite invasion assay. *Anopheles stephensi* mosquitoes were fed on infected Swiss-Webster mice. Mosquitoes infected with PbGFP-Luc, PKG-HA, and PKG T₆₁₉Q-HA parasites were maintained at 20°C. Sporozoites were obtained at days 18 to 21 postfeeding through dissections of salivary glands.

HepG2 cells (obtained from ATCC) were cultured in Dulbecco's modified Eagle medium (DMEM) (high glucose) supplemented with 10% fetal calf serum (FCS). Cells were seeded on collagen-coated multi-chambered slides for overnight growth at 37°C prior to addition of sporozoites. Invasion assays were performed using cells at 90% confluence, essentially as previously described (52). Sporozoites dissected in DMEM were pretreated with MG132, TSP, or vehicle for 30 min on ice in a volume of 20 μ l. Sporozoites (4×10^4 /well) were added to HepG2 cells in a final volume of 200 μ l of DMEM supplemented with 10% FCS. Cells were fixed in 4% paraformaldehyde 1.5 h after addition of sporozoites. Cells were blocked in 1% BSA-PBS before incubation with anti-circumsporozoite (CS) antibody (3D11; 1 μ g/ml) and anti-mouse Alexa 594. Cells were permeabilized with cold methanol, blocked, and incubated with 3D11 and anti-mouse Alexa 488. Extracellular sporozoites were quantified by determining the number of sporozoites that stained exclusively with anti-mouse Alexa 594. The total sporozoite number was quantified by determining the number of sporozoites immunostained with both Alexa 488 and Alexa 594. The effect of MG132 on sporozoite viability was determined by incubating MG132-treated sporozoites with propidium iodide (1 μ g/ml) for 10 min. Viable sporozoites were identified as those excluding propidium iodide through microscopic examination.

Statistical analysis. Statistical analysis was carried out using GraphPad Prism software, version 7.0.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/IAI.00523-18>.

SUPPLEMENTAL FILE 1, PDF file, 0.1 MB.

SUPPLEMENTAL FILE 2, PDF file, 0.5 MB.

SUPPLEMENTAL FILE 3, PDF file, 1.3 MB.

SUPPLEMENTAL FILE 4, PDF file, 0.1 MB.

SUPPLEMENTAL FILE 5, PDF file, 0.1 MB.

ACKNOWLEDGMENTS

We gratefully acknowledge H. Li and M. Bogyo for helpful discussions.

This work was supported by grants from the National Science Foundation (IOS-1146221), National Institutes of Health (R21AI094167 and 5R01AI133633), and Department of Defense (W81XWH-13-1-0429) to P.B., the National Institutes of Health (R01 GM104047) to B.E.T., UGA startup funds to V.M., and NIH T32 AI060546 and an ARCS Foundation Award to H.M.K. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

P.B., B.E.T., and V.M. designed the experiments; P.B. and B.E.T. wrote the manuscript; K.G., R.K., M.S., H.J.L., and H.M.K. performed the experiments. P.D. conducted the bioinformatic analyses.

REFERENCES

1. WHO. 2016. World malaria report 2016. World Health Organization, Geneva, Switzerland.
2. Hill AV. 2011. Vaccines against malaria. *Philos Trans R Soc Lond B Biol Sci* 366:2806–2814. <https://doi.org/10.1098/rstb.2011.0091>.
3. Kim JJ, Flueck C, Franz E, Sanabria-Figueroa E, Thompson E, Lorenz R, Bertinetti D, Baker DA, Herberg FW, Kim C. 2015. Crystal structures of the carboxyl cGMP binding domain of the *Plasmodium falciparum* cGMP-dependent protein kinase reveal a novel capping triad crucial for merozoite egress. *PLoS Pathog* 11:e1004639. <https://doi.org/10.1371/journal.ppat.1004639>.
4. Falae A, Combe A, Amaladoso A, Carvalho T, Menard R, Bhanot P. 2010. Role of *Plasmodium berghei* cGMP-dependent protein kinase in late liver stage development. *J Biol Chem* 285:3282–3288. <https://doi.org/10.1074/jbc.M109.070367>.
5. Govindasamy K, Jebiwott S, Jaijyan DK, Davidow A, Ojo KK, Van Voorhis WC, Brochet M, Billker O, Bhanot P. 2016. Invasion of hepatocytes by *Plasmodium* sporozoites requires cGMP-dependent protein kinase and calcium dependent protein kinase 4. *Mol Microbiol* 102:349–363. <https://doi.org/10.1111/mmi.13466>.
6. Collins CR, Hackett F, Strath M, Penzo M, Withers-Martinez C, Baker DA, Blackman MJ. 2013. Malaria parasite cGMP-dependent protein kinase regulates blood stage merozoite secretory organelle discharge and egress. *PLoS Pathog* 9:e1003344. <https://doi.org/10.1371/journal.ppat.1003344>.
7. Taylor HM, McRobert L, Grainger M, Sicard A, Dluzewski AR, Hopp CS, Holder AA, Baker DA. 2010. The malaria parasite cyclic GMP-dependent protein kinase plays a central role in blood-stage schizogony. *Eukaryot Cell* 9:37–45. <https://doi.org/10.1128/EC.00186-09>.
8. McRobert L, Taylor CJ, Deng W, Fivelman QL, Cummings RM, Polley SD, Billker O, Baker DA. 2008. Gametogenesis in malaria parasites is mediated by the cGMP-dependent protein kinase. *PLoS Biol* 6:e139. <https://doi.org/10.1371/journal.pbio.0060139>.
9. Moon RW, Taylor CJ, Bex C, Schepers R, Goulding D, Janse CJ, Waters AP, Baker DA, Billker O. 2009. A cyclic GMP signalling module that regulates gliding motility in a malaria parasite. *PLoS Pathog* 5:e1000599. <https://doi.org/10.1371/journal.ppat.1000599>.
10. Brochet M, Collins MO, Smith TK, Thompson E, Sebastian S, Volkman K, Schwach F, Chappell L, Gomes AR, Berriman M, Rayner JC, Baker DA,

- Choudhary J, Billker O. 2014. Phosphoinositide metabolism links cGMP-dependent protein kinase G to essential Ca^{2+} signals at key decision points in the life cycle of malaria parasites. *PLoS Biol* 12:e1001806. <https://doi.org/10.1371/journal.pbio.1001806>.
11. Brochet M, Billker O. 2016. Calcium signalling in malaria parasites. *Mol Microbiol* 100:397–408. <https://doi.org/10.1111/mmi.13324>.
 12. Alam MM, Solyakov L, Bottrill AR, Flueck C, Siddiqui FA, Singh S, Mistry S, Viskaduraki M, Lee K, Hopp CS, Chitnis CE, Doerig C, Moon RW, Green JL, Holder AA, Baker DA, Tobin AB. 2015. Phosphoproteomics reveals malaria parasite protein kinase G as a signalling hub regulating egress and invasion. *Nat Commun* 6:7285. <https://doi.org/10.1038/ncomms8285>.
 13. LaCount DJ, Vignali M, Chettier R, Phansalkar A, Bell R, Hesselberth JR, Schoenfeld LW, Ota I, Sahasrabudhe S, Kurschner C, Fields S, Hughes RE. 2005. A protein interaction network of the malaria parasite *Plasmodium falciparum*. *Nature* 438:103–107. <https://doi.org/10.1038/nature04104>.
 14. Deminoff SJ, Howard SC, Hester A, Warner S, Herman PK. 2006. Using substrate-binding variants of the cAMP-dependent protein kinase to identify novel targets and a kinase domain important for substrate interactions in *Saccharomyces cerevisiae*. *Genetics* 173:1909–1917. <https://doi.org/10.1534/genetics.106.059238>.
 15. Brown HF, Wang L, Khadka S, Fields S, LaCount DJ. 2011. A densely overlapping gene fragmentation approach improves yeast two-hybrid screens for *Plasmodium falciparum* proteins. *Mol Biochem Parasitol* 178:56–59. <https://doi.org/10.1016/j.molbiopara.2011.04.005>.
 16. Goldberg AL. 2012. Development of proteasome inhibitors as research tools and cancer drugs. *J Cell Physiol* 199:583–588. <https://doi.org/10.1083/jcb.201210077>.
 17. Panchal D, Bhanot P. 2010. Activity of a trisubstituted pyrrole in inhibiting sporozoite invasion and blocking malaria infection. *Antimicrob Agents Chemother* 54:4269–4274. <https://doi.org/10.1128/AAC.00420-10>.
 18. Gurnett AM, Liberator PA, Dulski PM, Salowe SP, Donald RG, Anderson JW, Wiltzie J, Diaz CA, Harris G, Chang B, Darkin-Rattray SJ, Nare B, Crumley T, Blum PS, Misura AS, Tamas T, Sardana MK, Yuan J, Biftu T, Schmatz DM. 2002. Purification and molecular characterization of cGMP-dependent protein kinase from Apicomplexan parasites. A novel chemotherapeutic target. *J Biol Chem* 277:15913–15922. <https://doi.org/10.1074/jbc.M108393200>.
 19. Mok J, Kim PM, Lam HY, Piccirillo S, Zhou X, Jeschke GR, Sheridan DL, Parker SA, Desai V, Jwa M, Camerani E, Niu H, Good M, Remenyi A, Ma JL, Sheu YJ, Sassi HE, Sopko R, Chan CS, De Virgilio C, Hollingsworth NM, Lim WA, Stern DF, Stillman B, Andrews BJ, Gerstein MB, Snyder M, Turk BE. 2010. Deciphering protein kinase specificity through large-scale analysis of yeast phosphorylation site motifs. *Sci Signal* 3:ra12. <https://doi.org/10.1126/scisignal.2000482>.
 20. Mitchell RD, Glass DB, Wong CW, Angelos KL, Walsh DA. 1995. Heat-stable inhibitor protein derived peptide substrate analogs: phosphorylation by cAMP-dependent and cGMP-dependent protein kinases. *Biochemistry* 34:528–534. <https://doi.org/10.1021/bi00002a018>.
 21. Tegge W, Frank R, Hofmann F, Dostmann WR. 1995. Determination of cyclic nucleotide-dependent protein kinase substrate specificity by the use of peptide libraries on cellulose paper. *Biochemistry* 34:10569–10577. <https://doi.org/10.1021/bi00033a032>.
 22. Wong A, Zhang YW, Jeschke GR, Turk BE, Rudnick G. 2012. Cyclic GMP-dependent stimulation of serotonin transport does not involve direct transporter phosphorylation by cGMP-dependent protein kinase. *J Biol Chem* 287:36051–36058. <https://doi.org/10.1074/jbc.M112.394726>.
 23. Alessi DR, Caudwell FB, Andjelkovic M, Hemmings BA, Cohen P. 1996. Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. *FEBS Lett* 399:333–338. [https://doi.org/10.1016/S0014-5793\(96\)01370-1](https://doi.org/10.1016/S0014-5793(96)01370-1).
 24. Yang J, Cron P, Good VM, Thompson V, Hemmings BA, Barford D. 2002. Crystal structure of an activated Akt/protein kinase B ternary complex with GSK3-peptide and AMP-PNP. *Nat Struct Biol* 9:940–944. <https://doi.org/10.1038/nsb870>.
 25. Belkina NV, Liu Y, Hao JJ, Karasuyama H, Shaw S. 2009. LOK is a major ERM kinase in resting lymphocytes and regulates cytoskeletal rearrangement through ERM phosphorylation. *Proc Natl Acad Sci U S A* 106:4707–4712. <https://doi.org/10.1073/pnas.0805963106>.
 26. Chen C, Ha BH, Thevenin AF, Lou HJ, Zhang R, Yip KY, Peterson JR, Gerstein M, Kim PM, Filippakopoulos P, Knapp S, Boggon TJ, Turk BE. 2014. Identification of a major determinant for serine-threonine kinase phosphoacceptor specificity. *Mol Cell* 53:140–147. <https://doi.org/10.1016/j.molcel.2013.11.013>.
 27. Xue L, Geahlen RL, Tao WA. 2013. Identification of direct tyrosine kinase substrates based on protein kinase assay-linked phosphoproteomics. *Mol Cell Proteomics* 12:2969–2980. <https://doi.org/10.1074/mcp.O113.027722>.
 28. Xue L, Wang WH, Iliuk A, Hu L, Galan JA, Yu S, Hans M, Geahlen RL, Tao WA. 2012. Sensitive kinase assay linked with phosphoproteomics for identifying direct kinase substrates. *Proc Natl Acad Sci U S A* 109:5615–5620. <https://doi.org/10.1073/pnas.1119418109>.
 29. Holt LJ, Tuch BB, Villen J, Johnson AD, Gygi SP, Morgan DO. 2009. Global analysis of Cdk1 substrate phosphorylation sites provides insights into evolution. *Science* 325:1682–1686. <https://doi.org/10.1126/science.1172867>.
 30. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, Gray NS, Yaffe MB, Marto JA, Sabatini DM. 2011. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. *Science* 332:1317–1322. <https://doi.org/10.1126/science.1199498>.
 31. Braun KA, Vaga S, Dombek KM, Fang F, Palmisano S, Aebersold R, Young ET. 2014. Phosphoproteomic analysis identifies proteins involved in transcription-coupled mRNA decay as targets of Snf1 signaling. *Sci Signal* 7:ra64. <https://doi.org/10.1126/scisignal.2005000>.
 32. Sacco F, Humphrey SJ, Cox J, Mischnik M, Schulte A, Klabunde T, Schafer M, Mann M. 2016. Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion. *Nat Commun* 7:13250. <https://doi.org/10.1038/ncomms13250>.
 33. Frohlich F, Olson DK, Christiano R, Farese RV, Jr, Walther TC. 2016. Proteomic and phosphoproteomic analyses of yeast reveal the global cellular response to sphingolipid depletion. *Proteomics* 16:2759–2763. <https://doi.org/10.1002/pmic.201600269>.
 34. Baum J, Richard D, Healer J, Rug M, Krnajska Z, Gilberger TW, Green JL, Holder AA, Cowman AF. 2006. A conserved molecular motor drives cell invasion and gliding motility across malaria life cycle stages and other apicomplexan parasites. *J Biol Chem* 281:5197–5208. <https://doi.org/10.1074/jbc.M509807200>.
 35. Bane KS, Lepper J, Sattler JM, Singer M, Reinig M, Klug D, Heiss K, Baum J, Mueller AK, Frischknecht F. 2016. The actin filament-binding protein coronin regulates motility in *Plasmodium* sporozoites. *PLoS Pathog* 12:e1005710. <https://doi.org/10.1371/journal.ppat.1005710>.
 36. Jones ML, Kitson EL, Rayner JC. 2006. *Plasmodium falciparum* erythrocyte invasion: a conserved myosin associated complex. *Mol Biochem Parasitol* 147:74–84. <https://doi.org/10.1016/j.molbiopara.2006.01.009>.
 37. Siden-Kiamos I, Pinder JC, Louis C. 2006. Involvement of actin and myosins in *Plasmodium berghei* ookinete motility. *Mol Biochem Parasitol* 150:308–317. <https://doi.org/10.1016/j.molbiopara.2006.09.003>.
 38. Baker RP, Wijetilaka R, Urban S. 2006. Two *Plasmodium* rhomboid proteases preferentially cleave different adhesins implicated in all invasive stages of malaria. *PLoS Pathog* 2:e113. <https://doi.org/10.1371/journal.ppat.0020113>.
 39. Li H, Ponder EL, Verdoes M, Asbjornsdottir KH, Deu E, Edgington LE, Lee JT, Kirk CJ, Demo SD, Williamson KC, Bogyo M. 2012. Validation of the proteasome as a therapeutic target in *Plasmodium* using an epoxyketone inhibitor with parasite-specific toxicity. *Chem Biol* 19:1535–1545. <https://doi.org/10.1016/j.chembiol.2012.09.019>.
 40. LaMonte GM, Almaliti J, Bibo-Verdugo B, Keller L, Zou BY, Yang J, Antonova-Koch Y, Orjuela-Sanchez P, Boyle CA, Vigil E, Wang L, Goldgof GM, Gerwick L, O'Donoghue AJ, Winzler EA, Gerwick WH, Otilite S. 2017. Development of a potent inhibitor of the *Plasmodium* proteasome with reduced mammalian toxicity. *J Med Chem* 60:6721–6732. <https://doi.org/10.1021/acs.jmedchem.7b00671>.
 41. Czesny B, Goshu S, Cook JL, Williamson KC. 2009. The proteasome inhibitor epoxomicin has potent *Plasmodium falciparum* gametocytocidal activity. *Antimicrob Agents Chemother* 53:4080–4085. <https://doi.org/10.1128/AAC.00088-09>.
 42. Li H, O'Donoghue AJ, van der Linden WA, Xie SC, Yoo E, Foe IT, Tilley L, Craik CS, da Fonseca PCA, Bogyo M. 2016. Structure- and function-based design of *Plasmodium*-selective proteasome inhibitors. *Nature* 530:233–236. <https://doi.org/10.1038/nature16936>.
 43. Gantt SM, Myung JM, Briones MR, Li WD, Corey EJ, Omura S, Nussenzweig V, Sinnis P. 1998. Proteasome inhibitors block development of *Plasmodium* spp. *Antimicrob Agents Chemother* 42:2731–2738. <https://doi.org/10.1128/AAC.42.10.2731>.
 44. Wang L, Delahunty C, Fritz-Wolf K, Rahlfs S, Helena Prieto J, Yates JR,

- Becker K. 2015. Characterization of the 26S proteasome network in *Plasmodium falciparum*. *Sci Rep* 5:17818. <https://doi.org/10.1038/srep17818>.
45. Ranek MJ, Terpstra EJ, Li J, Kass DA, Wang X. 2013. Protein kinase G positively regulates proteasome-mediated degradation of misfolded proteins. *Circulation* 128:365–376. <https://doi.org/10.1161/CIRCULATIONAHA.113.001971>.
46. Gillette TG, Hill JA. 2013. PKG primes the proteasome. *Circulation* 128:325–327. <https://doi.org/10.1161/CIRCULATIONAHA.113.003955>.
47. Collins GA, Goldberg AL. 2017. The logic of the 26S proteasome. *Cell* 169:792–806. <https://doi.org/10.1016/j.cell.2017.04.023>.
48. Hirano H, Kimura Y, Kimura A. 2016. Biological significance of co- and post-translational modifications of the yeast 26S proteasome. *J Proteomics* 134:37–46. <https://doi.org/10.1016/j.jprot.2015.11.016>.
49. Kikuchi J, Iwafune Y, Akiyama T, Okayama A, Nakamura H, Arakawa N, Kimura Y, Hirano H. 2010. Co- and post-translational modifications of the 26S proteasome in yeast. *Proteomics* 10:2769–2779. <https://doi.org/10.1002/pmic.200900283>.
50. Satoh K, Sasajima H, Nyomura KI, Yokosawa H, Sawada H. 2001. Assembly of the 26S proteasome is regulated by phosphorylation of the p45/Rpt6 ATPase subunit. *Biochemistry* 40:314–319. <https://doi.org/10.1021/bi001815n>.
51. Mollapour M, Neckers L. 2012. Post-translational modifications of Hsp90 and their contributions to chaperone regulation. *Biochim Biophys Acta* 1823:648–655. <https://doi.org/10.1016/j.bbamcr.2011.07.018>.
52. Sinnis P, De La Vega P, Coppi A, Krzych U, Mota MM. 2013. Quantification of sporozoite invasion, migration, and development by microscopy and flow cytometry. *Methods Mol Biol* 923:385–400. https://doi.org/10.1007/978-1-62703-026-7_27.
53. Workman CT, Yin Y, Corcoran DL, Ideker T, Stormo GD, Benos PV. 2005. eNoLOGOS: a versatile web tool for energy normalized sequence logos. *Nucleic Acids Res* 33:W389–W392. <https://doi.org/10.1093/nar/gki439>.